Overcoming these limitations through innovative research is crucial to harnessing the full potential of berberine and expanding its established uses
Immunovant (IMVT) Prices 7.37M Share Offering at $38/sh Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions
Asian-Australasian J
By supporting collagen production, providing antioxidant defense against the sun, and aiding in the skin's natural healing process, it addresses the root causes of lip aging and damage
Prolia (denosumab) Disease area(s): Bone health Manufacturer(s): Amgen 2024 Sales (USD): $4.37 billion Why it sold so well: In 2024, Amgens Prolia achieved strong sales, with global revenues increasing by 8% year-over-year to $4.37 billion for the year, driven primarily by volume growth
.png)
